389 results on '"Watterson, Daniel"'
Search Results
2. A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge
3. Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology
4. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
5. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
6. A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
7. Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses
8. Dynamin independent endocytosis is an alternative cell entry mechanism for multiple animal viruses.
9. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
10. Current knowledge of COVID-19: Advances, challenges and future perspectives
11. Epidemiology of respiratory syncytial virus in a community birth cohort of infants in the first 2 years of life
12. Antiviral Activities of Heparan Sulfate Mimetic RAFT Polymers Against Mosquito-borne Viruses
13. Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV‑2.
14. The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 gamma variant
15. A unified route for flavivirus structures uncovers essential pocket factors conserved across pathogenic viruses
16. Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses
17. A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice
18. Systems serology detects functionally distinct coronavirus antibody features in children and elderly
19. A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses
20. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody
21. Plugging the Leak in Dengue Shock
22. Mesoniviruses (Mesoniviridae)
23. Kinetics of severe dengue virus infection and development of gut pathology in mice
24. Determinants of Zika virus host tropism uncovered by deep mutational scanning
25. Cubane and Cyclooctatetraene Pirfenidones – Synthesis and Biological evaluation
26. Alternative cell entry mechanisms for SARS-CoV-2 and multiple animal viruses
27. The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 gamma variant.
28. The role ofN-glycosylation in spike antigenicity for the SARS-CoV-2 Gamma variant
29. Cloning, Expression, and Properties of the Microtubule-Stabilizing Protein STOP
30. Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology
31. Inactivation of SARS‐CoV ‐2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light
32. Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
33. An alpaca-derived nanobody recognizes a unique conserved epitope and retains potent activity against the SARS-CoV-2 omicron variant
34. Zika virus noncoding RNA cooperates with the viral protein NS5 to inhibit STAT1 phosphorylation and facilitate viral pathogenesis
35. Study Design and Operation for Evaluating Nipah Virus Vaccine Candidates Among Backyard Pigs of Indigenous Communities in Bangladesh
36. Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike protein
37. Democratising large scale instrument-based science through e-Infrastructure
38. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
39. Democratising large scale instrument-based science through e-Infrastructure
40. Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine
41. Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
42. Genetic characterization of archived bunyaviruses and their potential for emergence in Australia
43. A platform technology for generating subunit vaccines against diverse viral pathogens
44. Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern
45. Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants
46. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction
47. Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light
48. The distinguishing NS5-M114V mutation in American Zika virus isolates has negligible impacts on virus replication and transmission potential
49. Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration
50. Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.